Cyclo Therapeutics Net Income
| CYTHDelisted Stock | USD 0.72 0.06 9.09% |
As of the 16th of February 2026, Cyclo Therapeutics shows the risk adjusted performance of 0.051, and Mean Deviation of 4.64. Cyclo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cyclo Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cyclo Therapeutics' valuation are provided below:Cyclo Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cyclo |
Search Suggestions
| CY | Cypress Semiconductor | CompanyDelisted |
| CYD | China Yuchai International | Company |
| CYBAX | Calvert High Yield | Mutual Fund |
| CYA | Simplify Asset Management | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Cyclo Therapeutics reported net income of (20.06 Million). This is 105.88% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 103.51% higher than that of the company.
Cyclo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in net income category among its peers.
Cyclo Fundamentals
| Return On Equity | -226.64 | |||
| Return On Asset | -2.84 | |||
| Operating Margin | (35.46) % | |||
| Current Valuation | 34.87 M | |||
| Shares Outstanding | 32.74 M | |||
| Shares Owned By Insiders | 48.45 % | |||
| Shares Owned By Institutions | 11.44 % | |||
| Number Of Shares Shorted | 736.31 K | |||
| Price To Book | 59.10 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 1.08 M | |||
| Gross Profit | 794.48 K | |||
| EBITDA | (20.03 M) | |||
| Net Income | (20.06 M) | |||
| Cash And Equivalents | 4.29 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.03 M | |||
| Current Ratio | 2.93 X | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | (16.19 M) | |||
| Short Ratio | 5.58 X | |||
| Earnings Per Share | (0.90) X | |||
| Target Price | 0.95 | |||
| Beta | -0.57 | |||
| Market Capitalization | 23.59 M | |||
| Total Asset | 13.25 M | |||
| Retained Earnings | (83.86 M) | |||
| Working Capital | 3.85 M | |||
| Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Cyclo Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |